HomeCompareBICEF vs MRK

BICEF vs MRK: Dividend Comparison 2026

BICEF yields 5.58% · MRK yields 3.25%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 BICEF wins by $49.3K in total portfolio value
10 years
BICEF
BICEF
● Live price
5.58%
Share price
$63.08
Annual div
$3.52
5Y div CAGR
26%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$80.0K
Annual income
$17,808.64
Full BICEF calculator →
MRK
Merck & Co. Inc.
● Live price
3.25%
Share price
$94.80
Annual div
$3.08
5Y div CAGR
8.2%
Payout ratio
42%
After 10 yrs · $10,000 · DRIP
Portfolio value
$30.7K
Annual income
$950.29
Full MRK calculator →

Portfolio growth — BICEF vs MRK

📍 BICEF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodBICEFMRK
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, BICEF + MRK cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
BICEF pays
MRK pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

BICEF
Annual income on $10K today (after 15% tax)
$474.41/yr
After 10yr DRIP, annual income (after tax)
$15,137.34/yr
MRK
Annual income on $10K today (after 15% tax)
$276.16/yr
After 10yr DRIP, annual income (after tax)
$807.75/yr
At 15% tax rate, BICEF beats the other by $14,329.60/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of BICEF + MRK for your $10,000?

BICEF: 50%MRK: 50%
100% MRK50/50100% BICEF
Portfolio after 10yr
$55.4K
Annual income
$9,379.47/yr
Blended yield
16.93%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on MRK right now

BICEF
No analyst data
Altman Z
3.9
Piotroski
6/9
MRK
Analyst Ratings
25
Buy
11
Hold
1
Sell
Consensus: Buy
Price Target
$128.54
+35.6% upside vs current
Range: $100.00 — $150.00
Altman Z
4.0
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

BICEF buys
0
MRK buys
0
No recent congressional trades found for BICEF or MRK in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricBICEFMRK
Forward yield5.58%3.25%
Annual dividend / share$3.52$3.08
Payout ratio50%42%
1-year div growth0%5.5%
5-year div CAGR26%8.2%
Portfolio after 10y$80.0K$30.7K
Annual income after 10y$17,808.64$950.29
Total dividends collected$52.4K$6.1K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: BICEF vs MRK ($10,000, DRIP)

YearBICEF PortfolioBICEF Income/yrMRK PortfolioMRK Income/yrGap
1← crossover$11,403$703.25$11,192$351.54+$211.00BICEF
2$13,146$944.33$12,524$392.70+$622.00BICEF
3$15,348$1,281.94$14,015$438.65+$1.3KBICEF
4$18,185$1,762.46$15,682$489.96+$2.5KBICEF
5$21,917$2,459.02$17,547$547.23+$4.4KBICEF
6$26,941$3,489.93$19,632$611.16+$7.3KBICEF
7$33,878$5,051.72$21,963$682.53+$11.9KBICEF
8$43,731$7,480.63$24,571$762.18+$19.2KBICEF
9$58,162$11,370.69$27,486$851.08+$30.7KBICEF
10$80,042$17,808.64$30,745$950.29+$49.3KBICEF

BICEF vs MRK: Complete Analysis 2026

BICEFStock

Société BIC SA manufactures and sells stationery, lighter, shaver, and other products worldwide. It offers ball and coloring felt pens, markers, sticky notes, leads, whiteboards, and correction tapes, as well as graphite, coloring, mechanical, and other pencils; reusable notebooks, smart pens, erasers, crayons, art and craft kits, refillable shavers, razors shave cream, body and face lotions, finger painting products, and watercolors; permanent, single, metallic, and temporary tattoo markers; gel ink, roller, and fineliner pens; and ball and gel pen, color, and mechanical refills. The company also provides pocket, utility, decorated, non-decorated classic, electronic, and multipurpose lighters. In addition, it sells pantyhoses, batteries, and shaving preps; and advertising and promotional products. Further, the company is involved in the provision of delivery services; production of industrial equipment; and manufacture and distribution of IT solutions and consumer products, as well as in real estate and insurance activities. It markets its products primarily under the BIC, BIC Kids, Cello, Lucky, RocketBook, Tipp-Ex, BIC Wite-Out, DJEEP, BIC Soleil, Us, MADE FOR YOU, BIC Evolution, and BodyMark brands through a range of channels, including retail mass-market distributors, traditional stores, and office product stationers, as well as an e-commerce site. The company was founded in 1944 and is headquartered in Clichy, France.

Full BICEF Calculator →

MRKHealthcare

Merck is a Dividend Aristocrat with 14+ consecutive years of increases. Keytruda (pembrolizumab) is the world's best-selling cancer drug and drives exceptional cash generation. The company's oncology and vaccines pipeline provides long-term growth visibility beyond the Keytruda patent cliff in the 2030s.

Full MRK Calculator →
📬

Get this BICEF vs MRK comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

BICEF vs SCHDBICEF vs JEPIBICEF vs OBICEF vs KOBICEF vs MAINBICEF vs JNJBICEF vs ABBVBICEF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.